SCHEMBL27778184

SCHEMBL27778184

C[C@H](CC(=N)C(=O)OC(C)(C)C)OCc1ccccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.41
▸ PGR P06401 1/20 0.40
▸ ADORA3 P0DMS8 1/20 0.40
▸ PTGS1 P23219 1/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ PARP10 Q53GL7 1/20 0.37
▸ MAOB P27338 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ FDPS P14324 2/20 0.35
▸ PTPRA P18433 1/20 0.35
▸ ALOX5AP P20292 1/20 0.35
▸ POLB P06746 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ SYK P43405 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27954184 0.79 PTPRA (0.47) CYP1A2PGRADORA3PTGS1SLC6A2
SCHEMBL27613846 0.74 CYP3A4 (0.41) CYP1A2LMNAMAOBCYP2D6
SCHEMBL27613874 0.74 CYP3A4 (0.41) CYP1A2LMNAMAOBCYP2D6
SCHEMBL10237746 0.70 PGR (0.43) CYP1A2PGRADORA3PTGS1SLC6A2
SCHEMBL27766035 0.70 RIPK1 (0.44) RAB9AALDH1A1POLBMAPT
SCHEMBL14748865 0.70 CYP1A2 (0.43) CYP1A2PGRADORA3PTGS1SLC6A2
SCHEMBL1903216 0.69 GRM5 (0.45) CYP1A2PGRADORA3PTGS1SLC6A2
SCHEMBL10202636 0.69 PGR (0.45) CYP1A2PGRADORA3PTGS1SLC6A2
SCHEMBL740172 0.68 ALDH1A1 (0.46) CYP1A2PGRADORA3PTGS1SLC6A2
SCHEMBL12164511 0.68 NPC1 (0.49) CYP1A2PGRADORA3PTGS1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101679382-A 3-imidazolyl-indoles for the treatment of proliferative diseases NOVARTIS AG 2010-03-24 — — CN disclosed
Send feedback